Title:
B CELL-MEDIATED VACCINE LOADED WITH LIGAND OF NATURAL KILLER T CELL AND ANTIGEN
Document Type and Number:
Japanese Patent JP2011102320
Kind Code:
A
Abstract:
To provide an immune prophylaxis and prophylactic vaccine containing B cells mediated by α-galactosylceramide, a kind of glycolipid and a ligand of a natural killer T cell.
B cells, which are easily obtainable compared with dendritic cells, not only induce a similar level of cytotoxic T lymphocyte response to that of the conventional dendritic cell-based vaccine but also have a prophylactic and therapeutic effect on subcutaneous cancer and metastatic cancer. Thus, the B cell-mediated vaccine composition can be used as an antitumor immunotherapeutic agent.
More Like This:
| WO/2014/044690 | IMPROVED VACCINES |
| WO/2020/230792 | METHOD FOR DETERMINING ELIGIBILITY OF CANCER PATIENTS FOR PEPTIDE VACCINE THERAPY |
| WO/2016/103213 | COMPOSITION |
Inventors:
KANG CHANG-YUIL
CHUNG YEONSEOK
KO HYUN-JEONG
KIM YEON-JEONG
KIM BYUNG-SEOK
KO SUNG-YOUL
CHUNG YEONSEOK
KO HYUN-JEONG
KIM YEON-JEONG
KIM BYUNG-SEOK
KO SUNG-YOUL
Application Number:
JP2011007438A
Publication Date:
May 26, 2011
Filing Date:
January 18, 2011
Export Citation:
Assignee:
SEOUL NAT UNIV INDUSTRY FOUNDATION
International Classes:
A61K39/00; A61P31/04; A61P31/12; A61P33/00; A61P35/00; A61P37/04
Attorney, Agent or Firm:
Hatsushi Shimizu
Toshi Gobe
Kazuya Kawamoto
Koichi Niimi
Toshi Gobe
Kazuya Kawamoto
Koichi Niimi
Previous Patent: COMPOUND FOR NORMALIZATION OF SLEEP/WAKE CYCLE
Next Patent: GLYCOSIDE-CONTAINING LIPOSOME
Next Patent: GLYCOSIDE-CONTAINING LIPOSOME